X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs CIPLA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA CIPLA ASTRAZENECA PHARMA/
CIPLA
 
P/E (TTM) x 91.5 44.7 204.9% View Chart
P/BV x 13.0 3.7 354.0% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ASTRAZENECA PHARMA   CIPLA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
CIPLA
Mar-17
ASTRAZENECA PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,285622 206.6%   
Low Rs634458 138.3%   
Sales per share (Unadj.) Rs189.6181.9 104.3%  
Earnings per share (Unadj.) Rs-0.212.9 -1.6%  
Cash flow per share (Unadj.) Rs3.829.3 13.1%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs68.6155.7 44.1%  
Shares outstanding (eoy) m25.00804.51 3.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.13.0 170.4%   
Avg P/E ratio x-4,712.742.0 -11,230.0%  
P/CF ratio (eoy) x249.618.4 1,354.6%  
Price / Book Value ratio x14.03.5 403.0%  
Dividend payout %015.5 0.0%   
Avg Mkt Cap Rs m23,988434,516 5.5%   
No. of employees `0001.623.0 6.8%   
Total wages/salary Rs m1,60526,338 6.1%   
Avg. sales/employee Rs Th3,040.26,349.1 47.9%   
Avg. wages/employee Rs Th1,029.21,143.0 90.0%   
Avg. net profit/employee Rs Th-3.3449.3 -0.7%   
INCOME DATA
Net Sales Rs m4,740146,302 3.2%  
Other income Rs m922,287 4.0%   
Total revenues Rs m4,832148,589 3.3%   
Gross profit Rs m-13024,758 -0.5%  
Depreciation Rs m10113,229 0.8%   
Interest Rs m01,594 0.0%   
Profit before tax Rs m-13912,222 -1.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m51,798 0.3%   
Profit after tax Rs m-510,354 -0.0%  
Gross profit margin %-2.716.9 -16.2%  
Effective tax rate %-3.714.7 -24.9%   
Net profit margin %-0.17.1 -1.5%  
BALANCE SHEET DATA
Current assets Rs m2,72687,370 3.1%   
Current liabilities Rs m2,43533,081 7.4%   
Net working cap to sales %6.137.1 16.6%  
Current ratio x1.12.6 42.4%  
Inventory Days Days7487 84.8%  
Debtors Days Days4162 65.4%  
Net fixed assets Rs m1,035111,567 0.9%   
Share capital Rs m501,609 3.1%   
"Free" reserves Rs m942123,645 0.8%   
Net worth Rs m1,716125,254 1.4%   
Long term debt Rs m036,454 0.0%   
Total assets Rs m4,156209,532 2.0%  
Interest coverage xNM8.7-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.10.7 163.3%   
Return on assets %-0.15.7 -2.1%  
Return on equity %-0.38.3 -3.6%  
Return on capital %08.5 0.0%  
Exports to sales %5.734.2 16.7%   
Imports to sales %6.58.3 77.5%   
Exports (fob) Rs m27050,050 0.5%   
Imports (cif) Rs m30612,203 2.5%   
Fx inflow Rs m37551,066 0.7%   
Fx outflow Rs m47017,678 2.7%   
Net fx Rs m-9633,388 -0.3%   
CASH FLOW
From Operations Rs m-823,824 -0.0%  
From Investments Rs m-146-13,127 1.1%  
From Financial Activity Rs m862-13,239 -6.5%  
Net Cashflow Rs m709-2,478 -28.6%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 75.0 20.8 360.6%  
Indian inst/Mut Fund % 0.3 12.2 2.5%  
FIIs % 15.7 23.7 66.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 9.1 26.2 34.7%  
Shareholders   12,856 161,166 8.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ALEMBIC LTD  SUN PHARMA  PFIZER  FDC LTD.  AUROBINDO PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Lupin up 4%(01:30 pm)

After opening the day flat, share markets in India remained rangebound and are presently trading marginally above the dotted line.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 24, 2017 03:36 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS